Oncology Business Management | Specialty

Dr. Pecora on Patient Management Payments Under the OCM

August 12th 2016

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the Oncology Care Model (OCM) and other aspects of healthcare reform.

Dr. Pecora on How MACRA Needs Fine Tuning

August 12th 2016

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, talked about the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) and other aspects of healthcare reform.

Dr. Pecora on the Medicare Part B Drug Payment Model

August 12th 2016

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the Medicare Part B Drug Payment Model (OCM) and other aspects of healthcare reform.

In-Office Dispensing Is Better Value

August 10th 2016

With increased competition, the challenge in-office dispensing practices now face is to prove the value of what they do.

Clock Is Ticking on ICD-10 Grace Period

August 8th 2016

Oncology practices are facing a new deadline. When October 1 arrives, they will have to start coding with greater specificity and also get used to many new codes that CMS is going to activate.

A Tough State Makes a Tender Practice

August 7th 2016

New Mexico Cancer Center has a proud record of innovation—its managing partner helped create the Community Oncology Medical Home model in 2012—but the Albuquerque-based practice has still spent much of the past five years fighting to maintain its independence.

FDA Approves Pembrolizumab for Head and Neck Cancer

August 6th 2016

The FDA has granted an accelerated approval to pembrolizumab as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma following progression on a platinum-based chemotherapy.

FDA Grants Ribociclib Breakthrough Designation for Breast Cancer

August 3rd 2016

The FDA has granted a breakthrough therapy designation to the CDK4/6 inhibitor ribociclib in combination with letrozole for its potential as a frontline therapy for patients with HR-positive, HER2-negative advanced breast cancer.

Seeking an APM that Is Workable and Fair

August 2nd 2016

Blase Polite, MD, discusses the ramifications of CMS Acting Administrator Andy Slavitt's remarks and lingering concerns about MACRA.

Can the OCM Perform as Intended?

July 30th 2016

CMS, through the Center for Medicare & Medicaid Innovation, has launched an initiative called the Oncology Care Model that is designed to maintain clinical outcomes and reduce the total cost of care. The obvious first question is, has it been designed to do so?

FDA Grants Daratumumab Combos Breakthrough Designation for Myeloma

July 26th 2016

The FDA granted daratumumab (Darzalex) a breakthrough therapy designation for use in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone as a treatment for patients with multiple myeloma following at least 1 prior therapy.

Final Thoughts on NSCLC

July 19th 2016

What is on the Horizon for Immunotherapy in NSCLC?

July 19th 2016

Emerging Biomarkers for Lung Cancer

July 19th 2016

PD-L1 Biomarker Testing

July 19th 2016

Immunotherapy for Brain Metastases

July 19th 2016

Managing Toxicity in Immunotherapy for Lung Cancer

July 19th 2016

The Role of Immunotherapy in Metastatic NSCLC

July 19th 2016

Up-front Treatment Options for Squamous NSCLC

July 19th 2016

Progression in Non-Driver Adenocarcinoma

July 19th 2016